Plain-English translation of NCT06549595 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is comparing a new medication called paired with rituximab (an immunotherapy drug) against standard chemotherapy treatments for follicular lymphoma in people who have never received treatment before. The trial will enroll about 1,000 patients and test whether this newer combination is more effective and safer than the chemotherapy options doctors currently use. Your doctor will randomly assign you to receive either the medication with rituximab or one of three standard chemotherapy regimens.
Follicular lymphoma is a slow-growing blood cancer, but current chemotherapy treatments can have side effects and may not work as well as needed for everyone. This trial exists to see if this medication offers a better option — one that might work more effectively or with fewer side effects for newly diagnosed patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication () combined with rituximab immunotherapy on one of two schedules, or one of three standard chemotherapy regimens chosen by your doctor. The trial involves regular visits to the clinic where you'll receive treatment and have blood tests and scans to monitor how well the treatment is working and check for side effects. Your participation will continue through the treatment phase and follow-up visits to track your long-term response.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States